NEUPRO 4 MG / 24 HOUR
ROTIGOTINE : 4 MG / 24 HOUR · DIN 02403927 · UCB CANADA INC
Health Canada status: MARKETED
What is NEUPRO?
NEUPRO 4 MG / 24 HOUR contains ROTIGOTINE : 4 MG / 24 HOUR. It is listed in the Health Canada Drug Product Database under DIN 02403927, held by UCB CANADA INC, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 27-Jun-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NEUPRO used for?
NEUPRO (rotigotine) is indicated for: The treatment of the signs and symptoms of idiopathic Parkinson’s disease. NEUPRO may be used both as early therapy, without concomitant levodopa, and as an adjunct to levodopa. The symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02403927 |
|---|---|
| Brand name | NEUPRO |
| Generic / active ingredient | ROTIGOTINE : 4 MG / 24 HOUR |
| Manufacturer | UCB CANADA INC |
| Strength | 4 MG / 24 HOUR |
| Dosage form | PATCH |
| Route of administration | TRANSDERMAL |
| Schedule | Prescription |
| ATC code | N04BC09 ROTIGOTINE |
| AHFS class | 28:36.20.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Jun-2013 |
| Original market date | 2013-06-27 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code N04BC09 ROTIGOTINE. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NEUPRO | 1 MG / 24 HOUR | PATCH | UCB CANADA INC | MARKETED | DIN 02403897 |
| NEUPRO | 2 MG / 24 HOUR | PATCH | UCB CANADA INC | MARKETED | DIN 02403900 |
| NEUPRO | 3 MG / 24 HOUR | PATCH | UCB CANADA INC | MARKETED | DIN 02403919 |
| NEUPRO | 6 MG / 24 HOUR | PATCH | UCB CANADA INC | MARKETED | DIN 02403935 |
| NEUPRO | 8 MG / 24 HOUR | PATCH | UCB CANADA INC | MARKETED | DIN 02403943 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.